Active Ingredient History

  • Now
Vilanterol (INN, USAN) is an ultra-long-acting β2 adrenoreceptor agonist (ultra-LABA), which was approved in May 2013 in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD). Its pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3’,5’-adenosine monophosphate (cAMP). Increases in cyclic AMP are associated with relaxation of bronchial smooth muscle and inhibition of release of hypersensitivity mediators from mast cells in the lungs. Vilanterol is available in following combinations: a) with inhaled corticosteroid fluticasone furoate — fluticasone furoate/vilanterol (trade names Breo Ellipta , Relvar Ellipta; b) with muscarinic antagonist umeclidinium bromide — umeclidinium bromide/vilanterol (trade name Anoro Ellipta).   NCATS

  • SMILES: OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl
  • Mol. Mass: 486.44
  • ALogP: 4.61
  • ChEMBL Molecules:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Topical
  • Pro Drug: No

Combination drugs

( fluticasone (cutivate), vilanterol (Anoro Elipta) - other name: fluticasone furoate / vilanterol trifenatate 100/25 mcg )
4-{(1r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol | 4-(2-((6-((2-(((2,6-dichlorophenyl)methyl)oxy)ethyl)oxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol | breo ellipta | fluticasone furoate / umeclidinium bromide / vilanterol trifenatate | fluticasone furoate, umeclidinium bromide, vilanterol trifenatate | fluticasone furoate / vilanterol | fluticasone furoate / vilanterol trifenatate | gw6422444 | gw642444 | gw642444m | gw642444x | umeclidinium bromide / vilanterol | umeclidinium bromide / vilanterol trifenatate | vilanterol | vilantérol | vilanterol trifenatate


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue